BioNTech to Acquire
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
July 19, 2021 08:00 ET | BioNTech SE
Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North...
logo.png
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
April 15, 2021 07:00 ET | Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...
logo.png
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
March 30, 2021 07:57 ET | Arch Biopartners
TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...
logo.png
Arch Biopartners Closes Non-Brokered Private Placement
December 29, 2020 08:33 ET | Arch Biopartners
TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
BALMLOGO-purple-.png
Empowering Faith Communities to Champion Black Health Equity Amid A Pandemic
October 28, 2020 17:41 ET | The Balm In Gilead Inc.
RICHMOND, Va., Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Balm In Gilead Inc. is a leader in bringing public health and faith communities together to strategically address health disparities in the...
Scholar Rock logo2.png
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
January 09, 2020 07:30 ET | Scholar Rock
Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...